Get More Information on Colorectal Cancer Screening Market - Request Sample Report
The Colorectal Cancer Screening Market Size was valued at USD 15.36 billion in 2023 and is expected to reach USD 27.83 billion by 2032, growing at a CAGR of 6.85% from 2024-2032.
The colorectal cancer screening market is growing very robustly due to the increasing incidence of colorectal cancer, particularly in regions like China and Canada. For instance, in Canada, colorectal cancer has emerged as one of the top causes of cancer diagnoses, and the cases are increasingly found in younger populations. In 2023, in the United States, approximately 153,020 individuals will be diagnosed with CRC and 52,550 will die from the disease, including 19,550 cases and 3750 deaths in individuals younger than 50 years. Technological advancement with genetic testing and AI-assisted devices, such as GI Genius, is improving the detection and efficiency of screening. This FDA-approved AI-based device helps clinicians detect lesions and polyps during the colonoscopy procedure.
Screening methods, such as stool-based tests, colonoscopies, and CT colonography, are constantly evolving and applied on a wider scale across all strata. Government and private sector initiatives, such as the Ohio Colorectal Cancer Prevention Initiative, are further encouraging screening efforts, especially among those with genetic predispositions like Lynch syndrome. Increased awareness campaigns and government mandates, such as the U.S. Preventive Services Task Force (USPSTF) lowering the recommended age for screening of colorectal cancer to 45 also help to increase the pool of people eligible for screening.
Despite these developments, screening costs are still high, and access to healthcare is still not available in developing countries. Nevertheless, the colorectal cancer screening market will continue to grow steadily as the infrastructure of healthcare improves and the technologies used become more efficient. Non-invasive methods, like liquid biopsies and biomarker-based tests, are expected to increase patient compliance due to their comfort over traditional colonoscopies. Also, pharmaceutical companies are now using targeted therapies as well as preventive therapies, so complete approaches to the management of colorectal cancer keep surging.
Drivers
The increasing prevalence of colorectal cancer globally is a major driver of growth in the Colorectal Cancer Screening Market.
According to the American Cancer Society, colorectal cancer ranks the third most common type among both men and women in the United States, accounting for an estimated 106,000 new cases of colon cancer and 44,000 new cases of rectal cancer in the U.S. alone in 2023. Therefore, considering the increasing incidence, of the aging population, there is a greater demand for more widespread and accessible screening options that could make early detection easier.
Agencies such as the USPSTF have also reduced the age recommendation for screening for colorectal cancer from 50 to 45 years in those without known risk factors, thereby targeting an increased population and thus again driving the market forward. The latest studies have shown that this disease is on the rise among young people, especially in well-to-do countries, and thereby again emphasizes the need for early detection and regular follow-ups. Through screening initiatives, governments have taken more aggressive measures to fight the disease. For example, in Ohio, the Colorectal Cancer Prevention Initiative is a program that enhances public health campaigns that eventually increase the screening rate for people who are predisposed to colorectal cancer by genetic factors.
Age and Gender Distribution of Colorectal Cancer Cases and Deaths in the United States, 2023
The bar graph depicts the projected prevalence of new cases of colorectal cancer and deaths by age group and gender across the United States in 2023. The highest prevalence occurred among individuals aged 65 years and older, where they accounted for 56% of all new cases and 68% of all deaths, consistent with a higher risk for old age. Men also comprised slightly more than women of this age group. The 50–64 age group is second with 32% cases and 25% deaths, indicating an added necessity for increased screening interventions among middle-aged groups. Those aged less than 50 years are only 13% of cases and 7% of deaths, although there has been a progressive rise, especially in males, making the interventions crucial among all age groups.
Technological advancements are improving the effectiveness and accessibility of screening for colorectal cancer.
New tools, such as the FDA-approved AI-powered GI Genius device, help clinicians make more accurate diagnoses of colorectal lesions and polyps during a colonoscopy. The device uses machine learning algorithms to examine images in real time, which makes the screening process faster and less likely to result in missed diagnoses.
In addition, the development of non-invasive screening methods, such as liquid biopsies and biomarker-based tests, is providing patients with more comfortable alternatives to traditional colonoscopy. These advances are expected to increase patient compliance and expand the adoption of screening programs globally. For instance, liquid biopsy tests like Cologuard, which analyze stool samples for genetic markers of colorectal cancer, have been gaining popularity due to their ease of use and non-invasive nature.
Restraint
The cancer screening market is the high cost of screening procedures, particularly for advanced diagnostic tests and imaging technologies.
Technologies such as liquid biopsies, AI-based diagnostic tools, and genomic testing have a high potential for early cancer detection, but their costs are often out of reach, particularly in low-resource settings or developing countries. According to a report, many of these advanced screening methods require significant infrastructure and skilled healthcare providers, making them less accessible to disadvantaged populations.
In addition, a lack of large-scale healthcare infrastructure across some region’s limits cancer screening programs. Even standardized screenings such as colonoscopies and mammograms, which are standard, become unavailable in some regions when healthcare facilities are not nearby, especially in rural or remote areas. Patients may then receive delayed diagnosis and less favorable outcomes by not receiving screenings at the recommended frequencies, which in turn bounds the growth of the market.
Moreover, in some countries, healthcare insurance coverage for cancer screenings is limited, and out-of-pocket costs for patients can be a barrier to widespread screening adoption. This financial burden impacts both the patients who need screening and the healthcare systems that must allocate resources for these high-cost procedures. These economic challenges create significant obstacles to achieving universal screening goals and improving early detection rates globally.
By Type
The Colonoscopy segment dominated the market with a 50% market share, thstandard of screening for colorectal cancer because it can detect precancerous lesions and early stages of cancer, which immediately leads to intervention. This is a procedure where the interior of the colon can be visualized directly, thus allowing the removal of polyps during the process with a chance of preventing actual cancer. Despite its invasive nature and requirement for trained personnel, colonoscopy dominates the market due to its all-inclusive diagnostic ability and established position in routine screening guidelines, particularly in developed regions. It remains the first choice in hospital settings and is strongly recommended for those with an average or high risk of colorectal cancer.
In 2023, the Stool-based segment had the fastest growth and contributed with a market share of 38%. The Fecal Immunochemical Test (FIT), is the most rapidly expanding segment in the colorectal cancer screening market. FIT has gained popularity due to its non-invasive nature, ease of use, and affordability, making it an appealing option for widespread screening. These tests detect blood in the stool, which have shown high specificity, thus increasing their adoption. More expensive, stool DNA tests are gaining popularity because they can detect mutations that are genetically linked to colorectal cancer. The growth is so rapid in this segment owing to the preference for the non-invasive method, mostly preferred by those who refuse to undergo colonoscopies. Home tests where patients collect samples themselves and send them to a laboratory for analysis have increasingly resulted in a rise in the demand for stool-based tests, due to the convenience thereof. This shift is all also based on the healthcare industry's efforts toward early detection and hence complying with the screening of diverse population groups.
By End-User
The Hospitals & Clinics segment dominated the colorectal cancer screening market, mainly because these establishments offer a wide range of diagnostic services. They are well-staffed with advanced medical instruments, including colonoscopes, and highly skilled personnel that can perform polypectomy and biopsy procedures within a colonoscopy. Hospitals and clinics are important sites of colorectal cancer detection; these institutions are where a significant proportion of colonoscopies are conducted, thus forming the gold standard for screenings. Furthermore, many national screening guidelines encourage frequent screenings in hospitals and clinics, thus indicating an essential role for them in the early detection of cancers and interventions.
Diagnostic Imaging Centers are the fastest-growing segment in the market and are expected at a CAGR of 7.82% throughout the forecast period. This growth is due to the increasing adoption of non-invasive imaging techniques, specifically CT colonography, which is less invasive than the traditional colonoscopy method. Advanced imaging technologies also enable diagnostic imaging centers to provide a more accurate diagnostic result with greater patient comfort and lower risk. As a result, these centers are expanding their services to meet growing demand, particularly among patients seeking alternatives to invasive procedures. This segment's rapid expansion reflects the shift toward more patient-friendly options in colorectal cancer screening.
Need Any Customization Research On Colorectal Cancer Screening Market - Inquiry Now
In 2023, North America dominated the colorectal cancer screening market with a market share of 40%. This region is the biggest revenue generator in the market, due to the high incidence rates of colorectal cancer in the region. Cases are especially very high in the United States, where colorectal cancer is the third most common cancer. Advanced healthcare infrastructure, robust government initiatives for screening, and widespread adoption of innovative screening technologies like genetic tests and AI-assisted tools have supported North America's strong market position.
Asia Pacific is the fastest-growing region for colorectal cancer screening because of the rapidly increasing prevalence of this condition in countries such as China, Japan, and India. The demographic impact of an aging population, along with the introduction of national screening programs, is making a well for screening services. Improvements in healthcare infrastructure along with the expansion of sophisticated diagnostic tools in these countries are supporting rapid market growth. For instance, in China, which has recorded a sharp rise in cases, widespread screening efforts have been initiated to combat the rise of this disease.
Exact Sciences Corporation (Cologuard, Oncotype DX Colon Cancer Assay)
Abbott Laboratories (RealTime IDH1 Assay, mS9 Biomarker Screening Test)
Qiagen (Therascreen KRAS RGQ PCR Kit, PreAnalytiX PAXgene Stool Kit)
Roche Diagnostics (Elecsys CEA Assay, Cobas EGFR Mutation Test)
Sysmex Corporation (HISCL Tumor Marker Test, Colon Cancer Screening FOBT)
Eiken Chemical Co., Ltd. (OC-Sensor FIT System, LAMP DNA Amplification Test)
Fujirebio Diagnostics (Lumipulse G CEA, Lumipulse G FOB Plus)
Thermo Fisher Scientific (Oncomine Dx Target Test, QuantStudio Dx Real-Time PCR System)
Hologic, Inc. (Aptima KRAS Mutation Assay, Panther Fusion Assay)
Bio-Techne Corporation (ACD RNAscope Assay, Tumor Microenvironment Panel)
Guardant Health (Guardant360 Liquid Biopsy, Reveal Test for Minimal Residual Disease)
Natera, Inc. (Signatera, Prospera Transplant Assessment Test)
Siemens Healthineers (ADVIA Centaur CEA Assay, Atellica IM Tumor Marker Assay)
Invitae Corporation (Comprehensive Hereditary Cancer Panel, Genetic Risk Assessment for Colon Cancer)
PerkinElmer Inc. (LabChip GX Touch Nucleic Acid Analyzer, GSP Neonatal Screening Platform)
Epigenomics AG (Epi proColon, Epi proLung BL Reflex Assay)
Beckman Coulter, Inc. (Access CEA Tumor Marker Test, DxH 900 Hematology Analyzer)
Becton, Dickinson and Company (BD MAX Molecular Diagnostics System, FIT Hemoccult Test)
Illumina, Inc. (TruSight Oncology 500, NovaSeq Sequencing Platform)
Myriad Genetics, Inc. (myRisk Hereditary Cancer Test, myChoice CDx for Genetic Testing)
These suppliers provide essential components or materials for the products used in the colorectal cancer screening market:
Thermo Fisher Scientific Suppliers
Merck KGaA Suppliers
Integrated DNA Technologies (IDT) Suppliers
Agilent Technologies Suppliers
Bio-Rad Laboratories Suppliers
PerkinElmer Life Sciences Suppliers
Sigma-Aldrich (a subsidiary of Merck) Suppliers
Promega Corporation Suppliers
GE Healthcare Life Sciences Suppliers
Corning Incorporated Suppliers
September 2024: Exact Sciences chairman and CEO Kevin Conroy said: “We took a unique scientific approach to develop this test by combining a novel panel of markers. This led to data that improved upon what we previously thought was possible with a blood-based colorectal cancer screening test
November 2024: Qiagen is a key player in the colorectal cancer diagnostics market, emphasizing its role in developing advanced molecular diagnostic solutions. Qiagen’s innovations, particularly in non-invasive screening methods like stool-based DNA tests and its leadership in liquid biopsy technologies, position it strongly in this growing market. These contributions align with the global push for early cancer detection and personalized medicine.
October 2024: Roche Diagnostics Enhances Colorectal Cancer Screening with AI Owkin, in collaboration with Roche Diagnostics, launched MSIntuit CRC v2, an advanced AI-powered diagnostic for colorectal cancer (CRC). Integrated with Roche’s navify Digital Pathology software, it offered improved analysis of biopsies and resections, enhancing detection and treatment. This next-generation tool used cutting-edge machine learning and staining techniques to improve diagnostic precision, enabling tailored treatments and advancing pathology workflows.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 15.36 Billion |
| Market Size by 2032 | US$ 27.83 Billion |
| CAGR | CAGR of 6.85% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | •By Type (Stool-based, Colonoscopy, Others) •By End-User (Hospitals & Clinics, Clinical Laboratories, Diagnostic Imaging Centers, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Exact Sciences Corporation, Abbott Laboratories, Qiagen, Roche Diagnostics, Sysmex Corporation, Eiken Chemical Co., Ltd., Fujirebio Diagnostics, Thermo Fisher Scientific, Hologic Inc., Bio-Techne Corporation, Guardant Health, Natera Inc., Siemens Healthineers, Invitae Corporation, PerkinElmer Inc., Epigenomics AG, Beckman Coulter Inc., and other players. |
| Key Drivers | •The increasing prevalence of colorectal cancer globally is a major driver of growth in the colorectal cancer screening market. •Technological advancements are improving the effectiveness and accessibility of screening for colorectal cancer. |
| Restraints | •The cancer screening market is the high cost of screening procedures, particularly for advanced diagnostic tests and imaging technologies. |
Ans- The Colorectal Cancer Screening Market was valued at USD 15.36 billion in 2023 and is expected to reach USD 27.83 billion by 2032.
Ans – The CAGR rate of the Colorectal Cancer Screening Market during 2024-2032 is 6.85%.
Ans- The colonoscopy segment dominated the market by 50%
Ans- North America held the largest revenue share by 40%.
Ans- Asia Pacific is the fastest-growing region in the Colorectal Cancer Screening Market.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
5. Statistical Insights and Trends Reporting
5.1 Screening Uptake Trends (2023)
5.2 Shift Towards Non-Invasive Methods:(2023)
5.3 Rising Colorectal Cancer Incidence (2020-2032)
5.4 Colonoscopy’s Continued Relevance (2023)
5.5 Economic Impact (2023)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Colorectal Cancer Screening Market Segmentation, by Type
7.1 Chapter Overview
7.2 Stool based
7.2.1 Stool-based Market Trends Analysis (2020-2032)
7.2.2 Stool-based Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3 Fecal immunological test (FTI)
7.2.3.1 Fecal Immunological Test (FTI) Market Trends Analysis (2020-2032)
7.2.3.2 Fecal Immunological Test (FTI) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4 Fecal occult blood test (FOBT)
7.2.4.1 Fecal occult blood test (FOBT) Market Trends Analysis (2020-2032)
7.2.4.2 Fecal occult blood test (FOBT) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.5 Stool DNA test
7.2.5.1 Stool DNA Test Market Trends Analysis (2020-2032)
7.2.5.2 Stool DNA Test Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Colonoscopy
7.3.1 Colonoscopy Market Trends Analysis (2020-2032)
7.3.2 Colonoscopy Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Others
7.4.1 Others Market Trends Analysis (2020-2032)
7.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Colorectal Cancer Screening Market Segmentation, by End User
8.1 Chapter Overview
8.2 Hospitals & Clinics
8.2.1 Hospitals & Clinics Market Trends Analysis (2020-2032)
8.2.2 Hospitals & Clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Clinical laboratories
8.3.1 Clinical Laboratories Market Trends Analysis (2020-2032)
8.3.2 Clinical Laboratories Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Diagnostic Imaging Centers
8.4.1 Diagnostic Imaging Centers Market Trends Analysis (2020-2032)
8.4.2 Diagnostic Imaging Centers Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Others
8.5.1 Others Market Trends Analysis (2020-2032)
8.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Colorectal Cancer Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.2.3 North America Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.2.4 North America Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.2.5.2 USA Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.2.6.2 Canada Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.2.7.2 Mexico Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Colorectal Cancer Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.1.3 Eastern Europe Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.1.4 Eastern Europe Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.1.5 Poland
9.3.1.5.1 Poland Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.1.5.2 Poland Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.1.6 Romania
9.3.1.6.1 Romania Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.1.6.2 Romania Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.1.7.2 Hungary Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.1.8.2 Turkey Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.1.9.2 Rest of Eastern Europe Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Colorectal Cancer Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.2.3 Western Europe Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.4 Western Europe Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.5 Germany
9.3.2.5.1 Germany Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.5.2 Germany Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.6 France
9.3.2.6.1 France Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.6.2 France Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.7 UK
9.3.2.7.1 UK Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.7.2 UK Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.8 Italy
9.3.2.8.1 Italy Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.8.2 Italy Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.9 Spain
9.3.2.9.1 Spain Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.9.2 Spain Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.10.2 Netherlands Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.11.2 Switzerland Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.12 Austria
9.3.2.12.1 Austria Healthcare Predictive Analytic Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.12.2 Austria Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.3.2.13.2 Rest of Western Europe Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Colorectal Cancer Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.4.3 Asia Pacific Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.4.4 Asia Pacific Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.4.5.2 China Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.4.5.2 India Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.4.5.2 Japan Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.4.6.2 South Korea Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.7 Vietnam
9.4.7.1 Vietnam Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.2.7.2 Vietnam Healthcare Predictive Analytic Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.8 Singapore
9.4.8.1 Singapore Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.4.8.2 Singapore Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.9 Australia
9.4.9.1 Australia Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.4.9.2 Australia Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.4.10.2 Rest of Asia Pacific Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Colorectal Cancer Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.1.3 Middle East Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.1.4 Middle East Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.1.5 UAE
9.5.1.5.1 UAE Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.1.5.2 UAE Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.1.6.2 Egypt Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.1.7.2 Saudi Arabia Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.1.8.2 Qatar Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.1.9.2 Rest of Middle East Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Colorectal Cancer Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.2.3 Africa Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.2.4 Africa Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.2.5.2 South Africa Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.2.6.2 Nigeria Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.5.2.7 Rest of Africa
9.5.2.7.1 Rest of Africa Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.5.2.7.2 Rest of Africa Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Colorectal Cancer Screening Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.6.3 Latin America Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.6.4 Latin America Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.6.5.2 Brazil Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.6.6.2 Argentina Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.6.7 Colombia
9.6.7.1 Colombia Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.6.7.2 Colombia Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Colorectal Cancer Screening Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
9.6.8.2 Rest of Latin America Colorectal Cancer Screening Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10. Company Profiles
10.1 IBM Watson Health
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
110.1.4 SWOT Analysis
10.2 Optum
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 Cerner Corporation
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 SAS Institute
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 Oracle Health Sciences
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 Cognizant Technology Solutions
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 Allscripts Healthcare Solutions
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 Health Catalyst
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 GE Healthcare
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
10.10 Philips Healthcare
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segmentation
By Type
Stool based
Fecal immunological test (FTI)
Fecal occult blood test (FOBT)
Stool DNA test
Colonoscopy
Others
By EndUser
Hospitals & clinics
Clinical laboratories
Diagnostic Imaging Centers
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization to meet the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Healthcare Waste Management Market Size was valued at USD 34.08 Billion in 2023, and is expected to reach USD 68.03 Billion by 2032, and grow at a CAGR of 8.36% Over the Forecast Period of 2024-2032.
The Biosimulation Market Size was valued at USD 2.4 billion in 2023 and is expected to reach USD 8.4 billion by 2031, and grow at a CAGR of 17.0% over the forecast period 2024-2031.
The Healthcare Cold Chain Monitoring Market Size was valued at USD 2.29 billion in 2023 and is expected to reach USD 5.68 billion by 2032 and grow at a CAGR of 10.64% over the forecast period 2024-2032.
The Allergy Diagnostics Market size was valued at USD 4.91 billion in 2023 and is expected to reach USD 13.68 billion by 2032 at a CAGR of 12.06% during the forecast period of 2024-2032.
The AI in Cancer Diagnosis Market Size was USD 960.1 Million in 2023 and is projected to reach USD 2456 Million by 2032, growing at 11% CAGR.
The Personalized Nutrition Market Size was valued at USD 12.06 Billion in 2023, and is expected to reach USD 41.10 Billion by 2032, and grow at a CAGR of 15.04% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
